Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response

References

• Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–9. doi:10.1016/S0140-6736(16)30354-3.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. New Engl J Med. 2007;357(18):1810–1820. doi:10.1056/NEJMoa072252.
   PubMed Web of Science ®Google Scholar
• Cho JH, Lim JY, Cho JY, Katoh M. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. PLoS One. 2017;12(10):e0186362–e. doi:10.1371/journal.pone.0186362.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang Q, Hu Y, Li T, Yu J, Zhao L, Ye G, Deng H, Mou T, Cai S, et al. ImmunoScore signature: a prognostic and predictive tool in gastric cancer. Ann Surg. 2018;267:504–513. doi:10.1097/SLA.0000000000002116.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang X, Shen Z, Xu J, Qin J, Sun Y. Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric Cancer. 2015;18:740–750. doi:10.1007/s10120-014-0422-7.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu H, Shen Z, Lin C, Wang X, Qin J, Qin X, Xu J, Sun Y. Tumor-infiltrating neutrophils is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. Ann Surg. 2018;267(2):311–318. doi:10.1097/SLA.0000000000002058.
   PubMed Web of Science ®Google Scholar
• Goswami R, Kaplan MH. A brief history of IL-9. J Immunol. 2011;186:3283–3288. doi:10.4049/jimmunol.1003049.
   PubMed Web of Science ®Google Scholar
• Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol. 2010;10:683–687. doi:10.1038/nri2848.
   PubMed Web of Science ®Google Scholar
• Rojas-Zuleta WG, Sanchez E. IL-9: function, sources, and detection. Methods Mol Biol (Clifton, NJ). 2017;1585:21–35.
   PubMedGoogle Scholar
• Tan H, Wang S, Zhao L. A tumour-promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways. Clin Exp Pharmacol Physiol. 2017;44:213–221. doi:10.1111/1440-1681.12689.
   PubMed Web of Science ®Google Scholar
• Hsieh T-H, Hsu C-Y, Tsai C-F, Chiu -C-C, Liang -S-S, Wang T-N, Kuo P-L, Long C-Y, Tsai E-M. A novel cell-penetrating peptide suppresses breast tumorigenesis by inhibiting β-catenin/LEF-1 signaling. Sci Rep. 2016;6:19156. doi:10.1038/srep19156.
   PubMed Web of Science ®Google Scholar
• Lu Y, Hong S, Li H, Park J, Hong B, Wang L, Zheng Y, Liu Z, Xu J, He J, et al. Th9 cells promote antitumor immune responses in vivo. J Clin Invest. 2012;122(11):4160–4171. doi:10.1172/JCI65459.
   PubMed Web of Science ®Google Scholar
• Shou ZX, Jin X, Zhao ZS. Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer. Ann Surg. 2012;256:1014–1022. doi:10.1097/SLA.0b013e3182592f56.
   PubMed Web of Science ®Google Scholar
• Noh SH, Park SR, Yang H-K, Chung HC, Chung I-J, Kim S-W, Kim -H-H, Choi J-H, Kim H-K, Yu W, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–1396. doi:10.1016/S1470-2045(14)70473-5.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl J Med. 2006;355(1):11–20. doi:10.1056/NEJMoa055531.
   PubMed Web of Science ®Google Scholar
• Speiser DE, Ho P-C, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016;16:599. doi:10.1038/nri.2016.80.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. doi:10.1038/nrc3245.
   PubMed Web of Science ®Google Scholar
• Lin C, Liu H, Zhang H, Cao Y, Li R, Wu S, Li H, He H, Xu J, Sun Y, et al. Tryptase expression as a prognostic marker in patients with resected gastric cancer. BJS. 2017;104:1037–1044. doi:10.1002/bjs.10546.
   Google Scholar
• Wang JT, Li H, Zhang H, Chen YF, Cao YF, Li RC, Lin C, Wei YC, Xiang XN, Fang HJ, et al. Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. Ann Oncol. 2018;30:266–273. doi:10.1093/annonc/mdy505.
   Web of Science ®Google Scholar
• Jiang Y, Xie J, Han Z, Liu W, Xi S, Huang L, Huang W, Lin T, Zhao L, Hu Y, et al. Immunomarker support vector machine classifier for prediction of gastric cancer survival and adjuvant chemotherapeutic benefit. Clin Cancer Res. 2018;24(22):5574. doi:10.1158/1078-0432.CCR-18-0848.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun M, Zhao H, Huang Y, Li D, Mao D, Zhang Z, Zhu X, Dong X, Zhao X, et al. IL-9 exerts antitumor effects in colon cancer and transforms the tumor microenvironment in vivo. Technol Cancer Res Treat. 2019;18:1533033819857737. doi:10.1177/1533033819857737.
   Web of Science ®Google Scholar
• He J, Wang L, Zhang C, Shen W, Zhang Y, Liu T, Hu H, Xie X, Luo F. Interleukin-9 promotes tumorigenesis through augmenting angiogenesis in non-small cell lung cancer. Int Immunopharmacol. 2019;75:105766. doi:10.1016/j.intimp.2019.105766.
   PubMed Web of Science ®Google Scholar
• Ye Z-J, Zhou Q, Yin W, Yuan M-L, Yang W-B, Xiong X-Z, Zhang J-C, Shi H-Z. Differentiation and immune regulation of IL-9−producing CD4 + T cells in malignant pleural effusion. Am J Respir Crit Care Med. 2012;186(11):1168–1179. doi:10.1164/rccm.201207-1307OC.
   PubMed Web of Science ®Google Scholar
• Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, Jetten AM, Khoury SJ, Fuhlbrigge RC, Kuchroo VK, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med. 2012;18:1248–1253. doi:10.1038/nm.2856.
   PubMed Web of Science ®Google Scholar
• Abdul-Wahid A, Cydzik M, Prodeus A, Alwash M, Stanojcic M, Thompson M, Huang EHB, Shively JE, Gray-Owen SD, Gariépy J, et al. Induction of antigen-specific TH9 immunity accompanied by mast cell activation blocks tumor cell engraftment. Int J Cancer. 2016;139:841–853. doi:10.1002/ijc.30121.
   PubMed Web of Science ®Google Scholar
• Park J, Li H, Zhang M, Lu Y, Hong B, Zheng Y, He J, Yang J, Qian J, Yi Q, et al. Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy. Cancer Immunol Immunother. 2014;63(8):835–845. doi:10.1007/s00262-014-1557-4.
   PubMed Web of Science ®Google Scholar
• Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717–726. doi:10.1016/S1470-2045(16)00175-3.
   PubMed Web of Science ®Google Scholar
• Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15:457. doi:10.1038/nrc3973.
   PubMed Web of Science ®Google Scholar
• Nonomura Y, Otsuka A, Nakashima C, Seidel JA, Kitoh A, Dainichi T, Nakajima S, Sawada Y, Matsushita S, Aoki M, et al. Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients. Oncoimmunology. 2016;5:e1248327–e. doi:10.1080/2162402X.2016.1248327.
   PubMed Web of Science ®Google Scholar
• Wang C, Lu Y, Chen L, Gao T, Yang Q, Zhu C, Chen Y. Th9 cells are subjected to PD-1/PD-L1-mediated inhibition and are capable of promoting CD8 T cell expansion through IL-9R in colorectal cancer. Int Immunopharmacol. 2020;78:106019. doi:10.1016/j.intimp.2019.106019.
   PubMed Web of Science ®Google Scholar